Beszłej Aleksander, Grzesiak Magdalena
Katedra i Klinika Psychiatrii AM we Wrocławiu.
Psychiatr Pol. 2002 Nov-Dec;36(6 Suppl):115-23.
The paper presents results of the study on the efficacy and tolerability of mirtazapine treatment of patients with depression. The study was open and conducted in three centers. 65 out- and in-patients with diagnosis of depression was included. 50% reduction of the score in the HAM-D scale was obtained in 57%, according to MADRS scale--in 61% patients. Side effects were reported in 49% patients. The most frequent side effects were: drowsiness, fatigue, anxiety, sleepiness, weight increase, headache. The results of the study are comparable with other mirtazapine studies.
本文介绍了米氮平治疗抑郁症患者的疗效和耐受性研究结果。该研究为开放性研究，在三个中心进行。纳入了65例诊断为抑郁症的住院和门诊患者。根据汉密尔顿抑郁量表（HAM-D），57%的患者得分降低了50%；根据蒙哥马利-艾森伯格抑郁量表（MADRS），61%的患者得分降低。49%的患者报告有副作用。最常见的副作用为：嗜睡、疲劳、焦虑、困倦、体重增加、头痛。该研究结果与其他米氮平研究结果相当。
